Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
codrituzumab
- Development stage
- Phase 2
- Lead developer
- Chugai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Codrituzumab is a humanized monoclonal antibody that targets glypican‑3 (GPC3), an oncofetal protein highly expressed on the surface of certain tumor cells, particularly in hepatocellular carcinoma. By binding to GPC3, codrituzumab triggers antibody-dependent cellular cytotoxicity (ADCC), recruiting immune effector cells such as natural killer (NK) cells to induce tumor cell death. The drug has been primarily investigated for advanced or metastatic hepatocellular carcinoma and is not approved for marketing. Codrituzumab was originally developed by Perseus Proteomics and further developed by Chugai Pharmaceutical and Roche[1][5][7].
- Other names
- codrituzumabANTI-GPC3 MONOCLONAL ANTIBODY GC33ANTI-GPC-3 MONOCLONAL ANTIBODY GC33ANTI-GPC 3 MONOCLONAL ANTIBODY GC33Anti-Glypican 3 Monoclonal Antibody GC33Anti-Glypican3 Monoclonal Antibody GC33Anti-Glypican-3 Monoclonal Antibody GC33CODRITUZUMAB [INN]CODRITUZUMAB [WHO-DD]RG 7686RG7686RG-7686RO 5137382RO5137382RO-5137382U9I0PLD4HTU-9I0PLD4HTU 9I0PLD4HT
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on codrituzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on codrituzumab.